These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35849074)

  • 21. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.
    Demir M; Deyneli O; Yılmaz Y
    Turk J Gastroenterol; 2019 Mar; 30(3):266-270. PubMed ID: 30411703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
    Long MT; Zhang X; Xu H; Liu CT; Corey KE; Chung RT; Loomba R; Benjamin EJ
    Hepatology; 2021 Feb; 73(2):548-559. PubMed ID: 33125745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
    Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
    Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
    Condon S; Hu H; Kong M; Cave MC; McClain CJ
    Am J Med Sci; 2024 May; 367(5):310-322. PubMed ID: 38307172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis.
    Lee JI; Lee HW; Lee KS
    World J Gastroenterol; 2019 Sep; 25(33):4959-4969. PubMed ID: 31543686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.
    Calleja JL; Rivera-Esteban J; Aller R; Hernández-Conde M; Abad J; Pericàs JM; Benito HG; Serra MA; Escudero A; Ampuero J; Lucena A; Sánchez Y; Arias-Loste MT; Iruzubieta P; Romero-Gómez M; Augustin S; Crespo J
    Liver Int; 2022 Aug; 42(8):1783-1792. PubMed ID: 35643936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis.
    Pezzini MF; Cheinquer H; de Araujo A; Schmidt-Cerski CT; Sprinz E; Herz-Wolff F; Poeta J
    Curr HIV Res; 2021; 19(4):311-316. PubMed ID: 33632105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018.
    Zhang X; Heredia NI; Balakrishnan M; Thrift AP
    PLoS One; 2021; 16(6):e0252164. PubMed ID: 34081733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
    Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
    J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
    Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
    Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
    Martínez-Ortega AJ; Piñar Gutiérrez A; Lara-Romero C; Remón Ruiz PJ; Ampuero-Herrojo J; de Lara-Rodríguez I; Romero-Gómez M; García Luna PP; Soto-Moreno A
    Nutr Hosp; 2022 Oct; 39(5):1012-1018. PubMed ID: 36134588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
    Yu XY; Song XX; Tong YL; Wu LY; Song ZY
    Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled attenuation parameter accurately detects liver steatosis in people with HIV.
    Duarte M; Tien P; Ma Y; Noworolski SM; Korn N; Price JC
    AIDS; 2022 Dec; 36(15):2147-2152. PubMed ID: 35950941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Immunodeficiency Virus Is Associated With Elevated FibroScan-Aspartate Aminotransferase (FAST) Score.
    Price JC; Ma Y; Kuniholm MH; Adimora AA; Fischl M; French AL; Golub ET; Konkle-Parker D; Minkoff H; Ofotokun I; Plankey M; Sharma A; Tien PC
    Clin Infect Dis; 2022 Dec; 75(12):2119-2127. PubMed ID: 35511608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
    Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
    Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.